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Abstract
Protein lysine methyltransferases G9a and GLP modulate the transcriptional repression of a
variety of genes via dimethylation of Lys9 on histone H3 (H3K9me2) as well as dimethylation of
non-histone targets. Here we report the discovery of UNC0638, an inhibitor of G9a and GLP with
excellent potency and selectivity over a wide range of epigenetic and non-epigenetic targets.
UNC0638 treatment of a variety of cell lines resulted in lower global H3K9me2 levels, equivalent
to levels observed for small hairpin RNA knockdown of G9a and GLP with the functional potency
of UNC0638 being well separated from its toxicity. UNC0638 markedly reduced the clonogenicity
of MCF7 cells, reduced the abundance of H3K9me2 marks at promoters of known G9a-regulated
endogenous genes and disproportionately affected several genomic loci encoding microRNAs. In
mouse embryonic stem cells, UNC0638 reactivated G9a-silenced genes and a retroviral reporter
gene in a concentration-dependent manner without promoting differentiation.
Protein lysine methylation is increasingly recognized as a major signaling mechanism in
eukaryotic cells. This process has been most heavily studied in the context of epigenetic
regulation of gene expression through methylation of lysine residues of histone proteins1–6,
but a growing number of known non-histone substrates suggest that the impact of lysine
methylation is not limited to chromatin biology7–10. Protein lysine methyltransferases
(PKMTs) catalyze the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to
the ε-amino group of lysine residues of proteins, including histones1,11. Since the first
PKMT was characterized in 2000 (ref. 12), more than 50 human PKMTs have been
identified1,11. PKMTs show substantial variations in protein substrate selectivity and the
degree of methylation on lysine, from mono- to di- to trimethylation. Selective
pharmacological inhibition of individual PKMTs' catalytic activity in cellular systems is a
useful strategy for deciphering the complex signaling mechanisms of histone and protein
lysine methylation. However, very few small-molecule tools are currently available for
probing the activity of individual PKMTs13.
Growing evidence suggests that PKMTs are important in the development of various human
diseases11,14. In particular, G9a (also known as KMT1C or EHMT2), which was initially
identified as a histone H3 Lys9 (H3K9) methyltransferase15, is overexpressed in various
human cancers including leukemia8, prostate carcinoma8,16, hepatocellular carcinoma17 and
lung cancer18. It has been shown that knockdown of G9a inhibits prostate, lung and
leukemia cancer cell growth16,18,19. The closely related protein GLP (also known as
KMT1D or EHMT1) shares 80% sequence identity with G9a in their respective SET
domains and forms a heterodimer with G9a20. In addition to catalyzing mono- and
dimethylation of H3K9 (refs. 15,20), both G9a and GLP dimethylate Lys373 of the tumor
suppressor p53, inactivating p53's transcriptional activity8. Moreover, G9a has been shown
to be involved in cocaine addiction21, mental retardation22, maintenance of HIV-1 latency23
and DNA methylation in mouse embryonic stem (mES) cells24–26. Furthermore,
pharmacologic inhibition of G9a and GLP has been reported to facilitate reprogramming of
mouse fetal neural precursor cells into induced pluripotent stem (iPS) cells27,28. This broad
range of cellular and disease-related activities poses a challenge for understanding G9a- and
GLP-related biology and for the potential targeting of these proteins therapeutically. Thus,
selective, potent and cell- active chemical probes for G9a and GLP would be extremely
valuable tools for investigating the cellular role of these PKMTs, as well as for assessing
their potential as therapeutic targets.
Vedadi et al. Page 2













The recent report of BIX01294 (1), a small-molecule inhibitor of G9a and GLP29, was an
important advance, as this compound is, to our knowledge, the first potent and selective
PKMT inhibitor. BIX01294 has since been used successfully as a probe of G9a in cellular
reprogramming27,28 and reactivation of latent HIV-1 (ref. 23). BIX01294 at 4.1 μM reduced
the abundance of the H3K9me2 mark in bulk histones in several cell lines and reduced
H3K9me2 levels at G9a target genes29. However, BIX01294 was toxic to cells at
concentrations higher than 4.1 μM (ref. 29). This poor separation between the concentration
producing robust functional effects in cells and the concentration causing toxicity has
limited the compound's usefulness as a G9a and GLP chemical probe. To provide a high-
quality chemical probe30 of G9a and GLP with an improved ratio of toxicity to functional
potency (toxicity/function ratio, which is determined dividing the EC50 value of observed
toxicity by the IC50 value of the functional potency), we have explored this 2,4-diamino-6,7-
dimethoxyquinazo-line template. We have previously reported the discovery of UNC0224
and UNC0321 (2) as potent and selective G9a and GLP inhibitors and described robust
structure-activity relationships (SAR) of their analogs31,32. Other studies of the SAR of this
scaffold have resulted in the discovery of E72 as a potent and selective GLP inhibitor33.
However, UNC0321 (Supplementary Results, Supplementary Fig. 1) and E72 (ref. 33) are
less potent than BIX01294 in cellular assays.
Here we report that UNC0638 (3) is a potent, selective and cell-penetrant chemical probe for
G9a and GLP, with a toxicity/function ratio of >100, compared to <6 for BIX01294. We
describe the discovery of UNC0638 and its in vitro potency, selectivity, mechanism of
action and kinetics, X-ray cocrystal structure and robust on-target activities in cells. This
greatly improved, well-characterized chemical probe represents a substantial advance in
PKMT probe discovery and will enable better understanding of the epigenetic and cellular
role(s) of G9a and GLP.
RESULTS
Discovery of UNC0638
Previously, initial inhibitor design and synthesis based on the X-ray cocrystal structures of
the GLP-BIX01294 (PDB 3FPD)34 and G9a- UNC0224 (PDB 3K5K)31 complexes led us to
discover UNC0321, a potent and selective inhibitor of G9a and GLP32 (Scheme 1).
However, UNC0321 was less potent in cellular assays than BIX01294 (Supplementary Fig.
1), even though it was more potent than BIX01294 in biochemical assays. We hypothesized
that the poor cellular potency of UNC0321 was probably due to poor cell membrane
permeability. Here, to improve the cellular potency of this series of compounds, we
exploited the SAR of the quinazoline scaffold discovered previously31,32 and designed
several generations of new analogs aimed at increasing lipophilicity while maintaining high
in vitro potency. Among the newly synthesized compounds, UNC0638 (Scheme 1), which
has balanced in vitro potency and physicochemical properties aiding cell penetration,
showed high potency in cellular assays and was considerably less toxic to cells than
BIX01294 (see below). UNC0638 was efficiently synthesized via a novel seven-step
synthetic sequence (Supplementary Scheme 1). In contrast to our previous synthetic route to
UNC0321 (ref. 32), this new synthesis avoided the Mitsunobu reaction as the last synthetic
step and thus greatly facilitated purification of the final compounds.
In addition, we designed and synthesized UNC0737 (4) (Scheme 1), the N-methyl analog of
UNC0638, as a structurally similar but less potent G9a and GLP inhibitor for use as a
negative control. UNC0737 was designed to eliminate the hydrogen bond interaction seen in
the G9a-UNC0224 cocrystal structure between Asp1083 of G9a and the secondary amino
group at the 4-position of UNC0224's quinazoline ring31. Indeed, UNC0737 was >300-fold
less potent than UNC0638 in G9a and GLP biochemical assays (see below).
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UNC0638 is a potent and substrate-competitive inhibitor
The inhibitory effect of UNC0638 on G9a and GLP activity was first evaluated using the
fluorescence-based S-adenosyl-L-homocysteine hydrolase (SAHH)-coupled assay, which
monitors the conversion of the cofactor, SAM, to the cofactor product, S-adenosyl-L-
homocysteine (SAH)35. UNC0638 was a potent G9a (IC50 < 15 nM (n = 4)) and GLP
inhibitor (IC50 = 19 ± 1 nM (n = 2)) in these SAHH-coupled assays (Table 1). An
endoproteinase-coupled microfluidic capillary electrophoresis (MCE) assay36, which is
orthogonal and complementary to the SAHH-coupled assay, was also used to evaluate G9a
inhibition by UNC0638, yielding an IC50 < 10 nM (n = 3). In addition, UNC0638 displaced
a fluorescein-labeled 15-mer H3 peptide (residues 1–15) with high efficiency in a G9a
fluorescence-polarization assay, suggesting that UNC0638 binds in the substrate peptide-
binding site of G9a (Supplementary Fig. 2). UNC0638 also stabilized G9a and GLP in
differential scanning fluorimetry (DSF) experiments, with Tm shifts of 4 °C and 8 °C,
respectively, consistent with high-affinity binding (Supplementary Fig. 3).
We next determined detailed mechanism-of-action and Michaelis-Menten kinetic parameters
associated with both the peptide and SAM as a function of UNC0638 concentration (Fig.
1a–d). These experiments confirmed that UNC0638 was competitive with the peptide
substrate, as the Km of the peptide (Kmpeptide) increased linearly with UNC0638
concentration (Fig. 1b), and noncompetitive with cofactor SAM, as the apparent Km of SAM
(Kmapp) remained constant in the presence of increasing concentrations of the compound
(Fig. 1d). The Ki of UNC0638 was determined to be 3.0 ± 0.05 nM (n = 2). Consistent with
this, the Morrison Ki (ref. 37) for UNC0638 was 3.7 ± 0.2 nM (n = 3) (Supplementary Fig.
4).
Kinetics of the inhibition of G9a by UNC0638 was also studied using surface plasmon
resonance (SPR). UNC0638 bound G9a tightly, with rapid association (k = 2.12 × 106 1/Ms)
and disassociation (kd = 5.7 × 10−2 1/s) rates (Supplementary Fig. 5), consistent with a
classic reversible mechanism of inhibition of G9a. The Kd of UNC0638 measured from
equilibrium analysis of the Langmuir binding isotherms in the SPR studies was 27 nM,
consistent with results from homogeneous assays.
As expected, UNC0737, the N-methyl analog of UNC0638, was a poor inhibitor of G9a
(IC50 = 5,000 ± 200 nM (n = 2)) and GLP (IC50 > 10,000 nM (n = 2)) in the SAHH-coupled
assays (Supplementary Table 2). The combination of the high structural similarity between
UNC0737 and UNC0638 and the >300-fold loss of potency in UNC0737 compared to
UNC0638 makes UNC0737 an appropriate negative control for use in cellular and
functional assays.
UNC0638 is a selective inhibitor of G9a and GLP
The selectivity of UNC0638 over a wide range of epigenetic targets was evaluated (Table 1).
Notably, UNC0638 was inactive against other H3K9 (SUV39H1 and SUV39H2), H3K27
(EZH2), H3K4 (SETD7, MLL and SMYD3), H3K79 (DOT1L) and H4K20 (SETD8)
methyltransferases, as well as PRDM1, PRDM10 and PRDM12. In addition, UNC0638 was
inactive against protein arginine methyltransferases PRMT1 and PRMT3, and HTATIP, a
histone acetyltransferase. Of note, UNC0638 had weak but measurable activity against
JMJD2E (IC50 = 4,500 ± 1,100 nM (n = 3)), a Jumonji protein demethylase and DNA
methyltransferase DNMT1 (IC50 = 107,000 ± 6,000 nM (n = 2)). Nevertheless, the
selectivity of UNC0638 for G9a and GLP over JMJD2E was >200-fold, and selectivity for
G9a and GLP over DNMT1 was >5,000-fold.
We also evaluated the selectivity of UNC0638 over a broad range of non-epigenetic targets,
including G protein coupled receptors (GPCRs), ion channels, transporters and kinases
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(Supplementary Tables 3 and 4). UNC0638 was clean (<30% inhibition at 1 μM) against 26
out of 29 targets in the Ricerca Selectivity Panel. At 1 μM concentration, UNC0638 showed
64%, 90% and 69% inhibition of muscarinic M2, adrenergic α1A and adrenergic α1B
receptors, respectively. Because UNC0638 hit three GPCRs in the Ricerca Selectivity Panel,
we further assessed its selectivity against GPCRs by testing UNC0638 in the US National
Institute of Mental Health's Psychoactive Drug Screen Program Selectivity Panel, which
consists of a total of 45 targets, including 36 GPCRs. UNC0638 had <50% inhibition at 1
μM against 39 targets in the panel, and >50% inhibition at 1 μM against 6 targets in the
panel. Ki in the radio-ligand binding assay for each of the six interacting GPCRs was
subsequently determined. The Ki measurements showed UNC0638 was at least 100-fold
selective for G9a over these six GPCRs. In M1, M2 and M4 functional assays, UNC0638 had
no agonist activity, low antagonist potency against M1 and M4 (IC50 > 10,000 nM (n = 2)),
and modest antagonist potency against M2 (IC50 = 480 ± 10 nM (n = 2)). Furthermore,
UNC0638 was tested against a panel of 24 kinases and showed <10% inhibition at 1 μM
against these kinases. Therefore, we conclude that when used at appropriate concentrations
(for example, <500 nM), the effects of UNC0638 on histone or other lysine methylation
substrates can be interpreted as primarily due to the inhibition of G9a and GLP.
The selectivity of UNC0737 is summarized in Supplementary Table 2. Like UNC0638,
UNC0737 was inactive against SUV39H2, SETD7, SETD8 and PRMT3, had a binding-
affinity range of 60 to 1,000 nM (Ki values) for α1A, α2C, M1, M2 and M4 receptors, had
low to modest potency (IC50 800 to >10,000 nM) in M1, M2 and M4 functional assays and
was inactive against a panel of 24 kinases. The similar molecular profiles of UNC0737 and
UNC0638 against epigenetic targets (except G9a and GLP) and non-epigenetic targets make
UNC0737 an appropriate negative control in terms of selectivity.
Crystal structure of the G9a-UNC0638-SAH complex
An X-ray crystal structure of the G9a-UNC0638-SAH complex (2.56-Å resolution; Fig. 1e,f
and Supplementary Table 1) provides structural insight into the mechanism of action. First,
UNC0638 occupies the substrate binding groove and does not interact with the SAM
binding pocket. This finding is consistent with the results from the inhibitor-peptide-SAM
competition experiments. Second, the hydrogen of the secondary amino group at the 4-
position of the quinazoline ring indeed forms a hydrogen bond with Asp1083, explaining the
marked potency loss of UNC0737 compared to UNC0638. Finally, the lysine binding
channel is occupied by the 7-(3-pyrrolidin-1-yl-)propoxy side chain. Compared to the X-ray
crystal structures of the GLP-BIX01294 (PDB 3FPD)34 and G9a- UNC0224 (PDB 3K5K)31
complexes, the same binding mode was observed for UNC0638 (Supplementary Fig. 6).
UNC0638 is stable under cellular assay conditions
1H NMR and LC-MS analysis of a solution of UNC0638 (10 mM) in deuterated DMSO and
deuterated H2O (90:10 ratio) that had been kept at room temperature for 4 weeks indicated
that UNC0638 was stable under these conditions; no degradation products were found.
Incubation of UNC0638 with or without MCF7, U2OS or H1299 cells in two types of cell
media for 65 h also did not produce degradation products of UNC0638. In mouse drug
metabolism and pharmacokinetic studies, UNC0638 had high clearance, short half-life, high
volume distribution and low exposure after intravenous, oral or intraperitoneal
administration (Supplementary Table 5). Thus, although UNC0638 is probably not suitable
for in vivo animal studies owing to low exposure levels, its high stability under cellular
assay conditions, in combination with high potency and selectivity, makes UNC0638 an
ideal chemical tool for cell-based studies.
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UNC0638 has high cellular potency and low toxicity
G9a and GLP are the primary enzymes affecting dimethylation of histone H3K9 in
cells15,20. To assess the cellular potency of UNC0638, we used an H3K9me2 antibody cell
immunofluorescence or in-cell western assay. This assay allows rapid processing of multiple
samples for H3K9me2 immunofluorescence signal (Fig. 2a, green signal) and normalization
to cell number via the use of the nucleic acid dye DRAQ5 (Fig. 2a, red signal). We verified
the specificity of the antibody by comparison of dose-dependent dot blots and by the
reduced cellular immunofluorescence signal in G9a and GLP knockdown experiments (Fig.
2a). Initially, the data were normalized to total H3 levels (Supplementary Fig. 7); however,
this was found to be consistent with the DRAQ5 normalization, and subsequently the latter
was used. We characterized UNC0638 and UNC0737 in MDA-MB-231 cells because of
their robust H3K9me2 levels and good tolerance of G9a and GLP knockdown. In MDA-
MB-231 and MCF7 cells, treatment with several short hairpin RNAs (shRNAs) reduced G9a
and GLP to 25–40% of the levels in control experiments, and also yielded consistently lower
levels of H3K9me2 (Supplementary Fig. 8). In MDA-MB-231 cells, UNC0638 (48 h
exposure) reduced H3K9me2 levels in a concentration-dependent manner with an IC50 of 81
± 9 nM (n = 3), which indicates considerably higher potency than BIX01294 (IC50 = 500 ±
43 nM (n = 3)) (Fig. 2b). The maximum effect of UNC0638 in reducing H3K9me2 levels
was greater than that of BIX01294 and close, but not equal, to that of the double knockdown
of G9a and GLP via shRNA (Fig. 2b). Consistent with its poor in vitro potency, UNC0737
(negative control) showed poor cellular potency in the in-cell western (IC50 > 5,000 nM (n =
3); Fig. 2b) and chromatin immunoprecipitation (ChIP) assays (Supplementary Fig. 9).
We next studied the time course of effects of UNC0638 on cellular levels of H3K9me2.
Because H3K9me2 has a half-life of about 1 d (ref. 38), we hypothesized that exposure
beyond 48 h might result in even greater reduction of the mark. We found that H3K9me2
levels in MDA-MB-231 cells gradually decreased over the course of treatment (Fig. 2c).
After 4 d, the cellular H3K9me2 levels under treatment with 250 or 500 nM of UNC0638
were equal or very close to those of G9a and GLP knockdown cells. At both UNC0638
concentrations, changing the cell medium after 2 d (denoted “2+2d” in Fig. 2c) had little
effect compared with not changing the medium (denoted “4d” in Fig. 2c). Notably, reduced
cellular levels of H3K9me2 were still observed at the 4-d time point after cells were exposed
to UNC0638 for 2 d, followed by washout of the compound and another 2 d of culture
without the inhibitor (denoted “2+2dw” in Fig. 2c). The level of H3K9me2 at day 2+2dw
was inversely proportional to the original dosage of UNC0638, suggesting that residual
amounts of UNC0638 remain in the cells and can have a lasting effect. Inhibitor treatment
did not affect the protein levels of G9a or GLP (Supplementary Fig. 10) or the mRNA levels
of G9a (Supplementary Fig. 11), indicating the observed effects were due to inhibition of the
enzymatic function of the proteins and not to changes in protein abundance.
One of the desirable characteristics of a good chemical probe is low toxicity due to off-target
effects. Both UNC0638 (EC50 = 11,000 ± 710 nM (n = 3)) and UNC0737 (EC50 = 8,700 ±
790 nM (n = 3)) were considerably less toxic than BIX01294 (EC50 = 2,700 ± 76 nM (n =
3)) in an MTT assay (Fig. 2d). Notably, UNC0737 had cellular toxicity similar to that of
UNC0638, suggesting that the observed cellular toxicity is probably not due to inhibition of
G9a and GLP in this cell type. Thus, the toxicity/function ratio of UNC0638 was 138,
whereas the same ratio for BIX01294 was <6 (Fig. 2e,f). This much improved toxicity/
function ratio enables UNC0638 to be used in cell-based model systems over a range of
concentrations without interference from cellular toxicity.
Furthermore, we have evaluated the cellular potency and toxicity of UNC0638 in other
tumor and normal cell lines. UNC0638 had high potency, ranging from 48 to 238 nM, in
reducing H3K9me2 levels in breast, prostate, colon carcinomas and normal fibroblast cells,
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with the two prostate carcinoma cell lines, PC3 (IC50 = 59 nM) and 22RV1 (IC50 = 48 nM),
being the most sensitive (Supplementary Table 6). The EC50 for the cellular toxicity of
UNC0638 (from MTT assays) in these tumor and normal cell lines was considerably higher
than the corresponding IC50 for the functional effects. The toxicity/function ratio of
UNC0638 in these cell lines varied by up to ten-fold (19 for IMR90 compared with 233 for
PC3), but was well above the value of 6 observed for BIX01294 in MDA-MB-231 cells.
These results again support the conclusion that UNC0638 is suitable as a chemical probe of
G9a and GLP in a broad range of cell types without interference from potential off-target
toxicity.
Although UNC0638 is well tolerated by several cell types in terms of general cell viability,
we investigated whether it might affect the growth properties of cancer cell lines. At
concentrations of UNC0638 that considerably reduce H3K9me2 levels and for which acute
off-target toxicity is minimal, we monitored the effect of G9a and GLP inhibi tion on cell
growth using a clonogenicity assay. There was a marked concentration-dependent reduction
of clonogenicity in MCF7 cells upon treatment with UNC0638 or upon G9a or GLP
knockdown but much less effect on MDA-MB-231 cells (Supplementary Fig. 12). These
data show that inhibition of G9a and GLP can have differential phenotypic effects
depending on the cell type, possibly related to differences in epigenetic state or p53 status
(MCF7 cells have functional p53, whereas MDA-MB-231 cells do not).
MS analysis confirms that UNC0638 reduces H3K9me2 levels
To confirm the effect of UNC0638 on cellular levels of H3K9me2 and assess the potential
effect on other histone post-translational modification marks, we analyzed acid-extracted
histones from MDA-MB-231 cells treated with UNC0638 using quantitative MS–based
proteomics as previously described39. After treatment of MDA-MB-231 cells with
UNC0638 (1 μM for 48 h), the levels of H3K9me2 were considerably lower, similar to
those observed with shRNA double knockdown of G9a and GLP (Fig. 3a,b). BIX01294 (1
μM for 48 h) reduced the cellular levels of H3K9me2 to a lesser extent than UNC0638 did.
These results are consistent with the findings from the in-cell western assay. We note that
the levels of unmodified H3K9 were higher upon treatment with UNC0638, consistent with
decreased modification by G9a and GLP (Supplementary Fig. 13). In contrast, the levels of
H3K9me3 remained constant with all treatments (Fig. 3c,d), suggesting that, at least in these
cells, trimethylation of H3K9 is not dependent on prior dimethylation of H3K9 by G9a and/
or GLP. We also analyzed other well-known histone marks after treatment with UNC0638,
BIX01294 and shRNAs targeting G9a and GLP. With the exception of acetylation of histone
H3 Lys14 (H3K14ac), no changes in abundance were observed for 21 different modification
states of H3 and H4 (Supplementary Table 7). Notably, the levels of H3K14ac doubled both
with UNC0638 treatment and with G9a and GLP knockdown, suggesting a possible link or
cross-talk between H3K9me2 and H3K14ac (Supplementary Fig. 13). This result is
consistent with a previous finding in HEK293 cells in which G9a and GLP were knocked
down via siRNA39.
Genomic profiling of UNC0638-modulated H3K9me2 levels
To better understand how UNC0638 might regulate specific genes, we investigated the
H3K9me2 levels at genomic loci along chromosomes 3 and X (chr3 and chrX). In chromatin
immunoprecipitation on chip (ChIP-chip) experiments using a selective H3K9me2 antibody,
MCF7 cells treated with UNC0638 at 320 nM (the IC90 for H3K9me2 inhibition) for 14 d
had significantly fewer genomic regions containing H3K9me2 on chr3 and chrX (P < 2.2 ×
10−16; Fig. 4a and Supplementary Fig. 14). Lower levels of H3K9me2 were observed in the
MAGEA1 promoter in our ChIP-chip study (P = 4.3 × 10−3; Fig. 4b), and this was
confirmed in an independent ChIP-quantitative PCR (ChIP-qPCR) analysis. In agreement
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with previously reported data29, our ChIP-chip and ChIP-qPCR data show significant,
concentration-dependent reductions of H3K9me2 levels at the TBC1D5 and MAGEA2
promoters (P = 2.0 × 10−10 and 2.6 × 10−3, respectively) but not at the MAGEB4 promoter
(P = 0.07) after exposure to UNC0638 (Supplementary Fig. 15a–c). Thus, UNC0638 shows
robust on-target modulation of H3K9me2 levels, consistent with its activity as a selective
G9a and GLP inhibitor.
H3K9me2 is modestly correlated with euchromatic silenced genes40,41; however, it has also
been reported at active genes42. Notably, when we examined the genes with the greatest
reduction of H3K9me2 levels within their gene bodies, we found an enrichment of miRNA
genes: 25% of the top 100 most affected genes encoded miRNAs, whereas only 5% of the
probed genes on chr3 and chrX were miRNA genes (Supplementary Table 8). Furthermore,
under the conditions of these experiments (treatment for 14 d at 70 or 320 nM), we found
that the total levels of DNA methylation were not altered on chr3 and chrX in UNC0638-
treated MCF7 cells compared to control-treated cells (Fig. 4c and Supplementary Fig. 15d).
G9a inactivation has previously been shown to be ineffective in altering global DNA
methylation in human cancer cell lines (in contrast to mES cells)24. We note that although
our result supports the conclusion that inhibition of G9a catalytic activity does not produce
global changes in genomic DNA methylation, it does not exclude the possibility of small,
targeted changes below the resolution of these experiments. Taken together, these results
further support the value of UNC0638 as a tool for investigating the effects of specific and
global changes to H3K9me2 levels in human cells.
UNC0638 reactivates silenced gene expression in mES cells
Embryonic stem cells are unique in their ability to efficiently silence retroviruses through
epigenetic mechanisms including H3K9 dimethylation43. To investigate the ability of
UNC0638 to reactivate silent retrovirus vectors, we first determined the cellular potency of
UNC0638 and BIX01294 in J1 mES cells. Consistent with the above results, UNC0638
showed greater cellular potency than BIX01294 (at 48 h, IC50 = 138 and 2,041 nM,
respectively; Supplementary Fig. 16a). To establish retrovirus silencing, we infected J1 mES
cells with an HSC1-EF1α-EGFP-Puromycin retrovirus and selected for transduced cells
with a short puromycin treatment. We observed the initial 100% EGFP+ cell population
diminish to 30–36% EGFP+ cells as retrovirus silencing was gradually established over 150
d of extended culture.
To investigate the ability of the probe compounds to reactivate silent retrovirus vectors, we
followed EGFP expression by flow cytometry after treatment with UNC0638 (100, 250 or
500 nM), BIX01294 (2 μM) or UNC0737 (500 nM, as a negative control). Whereas
UNC0737 did not reactivate EGFP expression above the 36% EGFP+ cells seen in the
untreated sample, UNC0638 reactivated EGFP expression in a concentration-dependent
manner to a maximal level of 63% EGFP+ cells at day 10 (Fig. 5a and Supplementary Fig.
16c). BIX01294 reactivated expression reaching the level of 53% EGFP+ cells at day 10, an
expression level exceeded when cells were treated with UNC0638 at 250 nM, one-eighth the
concentration of BIX01294. Moreover, we observed cell morphology changes under
BIX01294 treatment, suggesting that this inhibitor may induce cell differentiation. By day
12, BIX01294-treated cells had arrested or died, whereas UNC0638 reactivated EGFP
expression in 75% of cells without showing morphological signs of cell differentiation (Fig.
5a). At day 10 of BIX01294 treatment, only 65% of cells were positive for the pluripotency
marker SSEA1 (Supplementary Fig. 16b). In contrast, UNC0638 treatment maintained
expression of the SSEA1 pluripotency marker: the level of marker in cells treated with 100
nM of UNC0638 (97% SSEA1+ cells) was indistinguishable from that in UNC0737-treated
cells or untreated cells. We conclude that inhibition of G9a with UNC0638 functionally
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reactivates silent retrovirus vectors without promoting differentiation into SSEA1− cells and
is considerably more potent than BIX01294 treatment.
We next tested whether MAGEA2 and DUB1, genes previously shown to be reactivated in
G9a-knockout mES cells25,44, could be reactivated with UNC0638 treatment in J1 mES
cells. At day 10, DUB1 and MAGEA2 genes were more highly expressed in UNC0638 than
in untreated or UNC0737-treated cells (Fig. 5b). Similar to the results for retroviral vector
reactivation, mRNA levels of DUB1 and MAGEA2 genes showed a concentration-
dependent increase upon treatment with UNC0638. We note that reactivation of endogenous
genes occurred by day 3 (Supplementary Fig. 16d), whereas EGFP retrovirus reactivation
was first evident by flow cytometry at day 7 (Fig. 5a).
In addition to directly methylating H3K9 (ref. 20), G9a has been reported to indirectly
facilitate DNA methylation in mES cells24–26. We first analyzed the presence of H3K9me2
by ChIP on the EGFP provirus and the endogenous MAGEA2 promoter and found that
UNC0638 treatment decreased H3K9me2 at both targets by day 3, with a further decrease
by day 7 (Fig. 5c,d). To test whether this reduction of H3K9me2 affects DNA methylation,
we performed bisulfite sequencing on the retrovirus long terminal repeat and MAGEA2
promoter after 10 d of treatment. Both regions were hypermethylated in untreated or
UNC0737-treated mES cells. In contrast, UNC0638 treatment induced DNA
hypomethylation in a concentration-dependent manner (Fig. 5e). These results suggest that
inhibition of gene silencing by UNC0638 primarily drives H3K9me2 loss to reactivate gene
expression and facilitates DNA hypomethylation in mES cells.
DISCUSSION
Protein lysine methyltransferase G9a has been implicated in various human diseases
including leukemia8, prostate cancer8,16, liver cancer17, lung cancer18, drug addiction21,
mental retardation22 and maintenance of HIV-1 latency23. Given the broad areas of biology
in which G9a and GLP have a role, a high-quality chemical probe of these two PKMTs
would be very valuable for dissecting the molecular mechanism(s) of these activities, the
cell types in which they are relevant and which diseases (if any) would benefit from their
inhibition. Here we report the discovery and characterization of UNC0638, which has all the
properties of a high-quality chemical probe30. (i) UNC0638 is a potent, substrate-
competitive inhibitor of G9a (IC50 < 15 nM, Ki = 3 nM) and the closely related GLP (IC50 =
19 nM). (ii) It is selective for G9a and GLP over a wide range of epigenetic and non-
epigenetic targets. (iii) It is highly active in cells: at 250 nM concentration, it reduces the
levels of H3K9me2 by ~60–80% in a variety of cell lines, similar to the reductions seen for
shRNA knockdown of G9a and GLP, and modulates expression of known G9a-regulated
genes. (iv) UNC0737, an N-methyl derivative of UNC0638, is >300-fold less potent against
G9a and GLP, with similar selectivity and cellular toxicity compared to UNC0638, and
therefore is a useful negative control. (v) UNC0638 has low cellular toxicity in seven cell
lines tested at functional doses. Notably, the greatly improved cellular toxicity/function ratio
relative to the previously available probe, BIX01294, makes UNC0638 much more versatile
as a chemical probe. (vi) Finally, a useful chemical probe must be available to the biological
research community. As such, we have made UNC0638 available through a commercial
vendor (Sigma-Aldrich).
Our proteomics and immunofluorescence data show that pharmacologic inhibition of G9a
and GLP with UNC0638 leads to global reductions in H3K9me2 levels, comparable to those
achieved with shRNAs. However, the genomic regions specifically marked with H3K9me2
vary with cell type and possibly with disease state19–21,23,45. Similarly, the cellular levels of
G9a and GLP also vary with cell type and disease state8. Indeed, we observed considerable
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variation in the global concentration-response behavior of UNC0638 in six cancer cell lines
and human fibroblasts. We also observed a marked growth-inhibitory effect in MCF7 cells
but not MDA-MB-231 cells at moderate UNC0638 concentrations under which H3K9me2
levels are fully suppressed. Given the association of G9a and GLP with DNMTs46,47 and
repression of tumor suppressor p53 (refs. 8,48), there may be specific epigenetic cellular
states (in particular, H3K9me2-mediated repression of a specific set of genes and/or p53
status) in which cells are selectively vulnerable to G9a and GLP inhibition. UNC0638 will
be a useful tool to search for such types of cancer or other disease-related epigenetic states.
BIX01294 is likely to be less effective in such studies owing to off-target toxic effects
encountered at or near its required concentration for full H3K9me2 suppression.
It is notable that most studies of G9a and GLP to date have used knockout or knockdown of
G9a and/or GLP, whereas UNC0638 inhibits only the enzymatic function of G9a and GLP,
and does not affect the protein and mRNA levels, thereby preserving a potential scaffolding
function in the many protein complexes reported for G9a and/or GLP20,46–49. For example,
it has been shown that catalytic activity of G9a or GLP is not required for all of its
function25,26. This may explain the milder phenotype of UNC0638 compared to
knockdowns of G9a and GLP, and it suggests that UNC0638 can be used to separate
enzymatic from non-enzymatic functions of these proteins.
We also show that UNC0638 can reactivate endogenous genes and silenced retroviral
reporters in mES cells, further implicating H3K9me2-mediated repression in these
processes. Retroviral silencing is a reliable criterion for identification of fully reprogrammed
cells and is a good indicator of pluripotency50. UNC0638 reduced H3K9me2 on endogenous
genes and retrovirus vectors within 3 d, and DNA hypomethylation was observed by day 10,
when the cells had already reactivated expression. Together, these results suggest that a
cascade of events is involved in the reactivation of silenced genes, and concentration-
dependent inhibition of G9a by UNC0638 drives this process. Therefore, UNC0638 is a
potent chemical tool for modulating G9a-related activities in cells to alter their expression
profiles and epigenetic landscapes, to assist in manipulating their cell identity and
phenotype, and to decipher the timing and inter-relationship of H3K9me2 and DNA
methylation in gene silencing.
METHODS
Biochemical assays
SAHH-coupled assay, peptide displacement, DSF and DSLS assay protocols are described
in Supplementary Methods. Morrison Ki and IC50 in G9a MCE assay were determined as
described36. Details of other selectivity assays are included in Supplementary Methods.
Cell immunostaining (in-cell western)
We added 2% (w/v) formaldehyde in PBS to fix cells for 15 min. After five washes with
0.1% (v/v) Triton ×100 in PBS, cells were blocked for 1 h with 1% (w/v) BSA in PBS.
Three of four replicates were exposed to primary H3K9me2 antibody, Abcam no. 1220 at
1:800 dilution in 1% BSA and PBS for 2 h. One replicate was reserved as a background
control. The wells were washed five times with 0.1% (v/v) Tween 20 in PBS, then
secondary IR800-conjugated antibody (LiCor) and a nucleic acid–intercalating dye, DRAQ5
(LiCor), were added for 1 h. After five washes with 0.1% Tween 20 in PBS, the plates were
read on an Odyssey (LiCor) scanner at 800 nm (H3K9me2 signal) and 700 nm (DRAQ5
signal). Fluorescence intensity was quantified, normalized to the background and then to the
DRAQ5 signal, and expressed as a percentage of control.
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Quantitative MS analysis of histones
Histones from MDA-MB-231cells were extracted using standard acid procedures and
analyzed after chemical derivatization by propionic anhydride and trypsin as described39.
Digested histone samples were analyzed by LC-MS/MS on an Orbitrap mass spectrometer
as described39. All data were manually verified.
ChIP-chip
ChIP samples were amplified for arrays using a whole-genome amplification (WGA)
method (reference is provided in Supplementary Methods). In WGA, DNA fragments are
primed to generate a library of DNA fragments with a common end sequence. The library
then is replicated using linear, isothermal amplification, followed by a limited round of
geometric PCR amplifications. The GenomePlex Complete WGA kit (Sigma) was used for
library preparation. ChIP samples concentrated to 10 μl were mixed with 2 μl library-
preparation buffer and then with 1 μl library-stabilization solution. Samples were incubated
at 95 °C for 2 min and afterwards immediately cooled on ice. Each sample was mixed with 1
μl of library-preparation enzyme and incubated as follows: 16 °C for 20 min, 24 °C for 20
min, 37 °C for 20 min, 75 °C for 5 min, 4 °C hold. Amplification of the samples was
completed with the GenomePlex WGA kit (Sigma). Each sample was combined with 44 μl
nuclease-free water, 7.5 μl Amplification Master Mix, 3 μl dNTP/dUTP mix (10 mM dATP,
10 mM dCTP, 10 mM dGTP, 8 mM dTTP and 2 mM dUTP) and 5 μl WGA DNA
polymerase. Amplified samples were purified using the QIAquick PCR purification kit
(Qiagen) and then processed for array hybridization as described below. Samples exposed to
the H3K9me2 antibody or IgG control antibody were hybridized to the arrays (n = 2 per
group).
Reactivation of retrovirus expression in mES cells
J1 mES cells were cultured (reference is provided in Supplementary Methods) in DMEM
with 15% (v/v) ES-qualified FBS supplemented with 4 mM L-glutamine, 0.1 mM MEM non-
essential amino acids, 1 mM sodium pyruvate, 0.55 mM 2-mercaptoethanol and purified
recombinant leukemia inhibitory factor on 0.1% gelatin-coated plates. Cells were infected
with a self-inactivated HSC1 retroviral vector (reference is provided in Supplementary
Methods) engineered to harbor an EGFP-Puromycin biscistronic reporter gene controlled by
the human EF1α promoter. EGFP gene expression was analyzed by flow cytometry.
Pluripotency of mES cells was tested by SSEA1 (a surface maker of mouse undifferentiated
cells) immunostaining and also measured by flow cytometry. Briefly, to perform flow
cytometry, we fixed trypsinized cells with 2% formaldehyde in phosphate-buffered saline
with 2% (v/v) FBS for 10 min at room temperature. Cells were then suspended in PBS with
2% (v/v) of serum (flow buffer) and filtered through 70-μm nylon membranes. EGFP
expression analyses were performed by LSRII flow cytometer (Becton-Dickinson) using
CellQuest Pro software. SSEA1 (a surface maker of mouse undifferentiated cells)
immunostaining was performed on non-permeabilized fixed cells. They were incubated with
mouse IgM antibody to SSEA1 (DSHB, MC-480) for 30 min at 4 °C. After being washed
three times with flow buffer, cells were incubated for 30 min with secondary antibody,
Phycoerythrin-Cy5.5 (PE-Cy5.5) anti-mouse IgM (eBioscience), at 4 °C. Cells were washed
three times in the flow buffer, and SSEA1 immunostaining was analyzed by LSRII flow
cytometer. We excluded cell debris were excluded from analysis by using forward- and side-
scatter gating. Uninfected J1 ES cell line was used as a negative control to adjust EGFP
fluorescence measurements. SSEA1 immunostaining of mouse embryonic fibroblast was
used as a negative control cell line for SSEA1 cell measurement. Reactivation of
endogenous genes, ChIP of endogenous gene and retrovirus, and DNA methylation analysis
in mES cells are described in Supplementary Methods.
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Synthesis of UNC0638 and UNC0737, UNC0638 mechanism-of-action and kinetic studies,
determination of X-ray crystal structure of the G9a-UNC0638-SAH complex, UNC0638
stability studies, mouse drug metabolism and pharmacokinetic studies, cell growth, MTT,
shRNA, ChIP, western blotting, immunofluorescence microscopy, clonogenicity,
immunostaining flow cytometry, reverse transcription–qPCR, DNA extraction, enrichment
of unmethylated DNA fraction, and microarray experiments and data analysis are described
in Supplementary Methods.
Accession codes
Protein Data Bank: Coordinates and structure factors for the cocrystal structure of the G9a–
UNC0638–SAH complex have been deposited with accession code 3RJW.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. UNC0638 competes with the peptide substrate but not with the cofactor SAM
We determined the velocity of the reaction by measuring the conversion of substrate to
product at six time points spanning 100 min, analyzed these data by linear regression to
determine initial steady-state enzyme velocity and fitted them to Michaelis-Menten kinetics.
The Km values of the peptide and SAM were then plotted as a function of UNC0638
concentrations. (a,b) UNC0638 is competitive with the H3K9 peptide substrate, as Kmpeptide
increases linearly with compound concentration. (c,d) UNC0638 does not compete with the
cofactor SAM, as Kmapp was not affected by the compound. (e,f) The X-ray cocrystal
structure of the G9a-UNC0638-saH complex confirms the mechanism of action of
UNC0638. UNC0638 (in gray, blue and red sticks) occupies the peptide binding groove and
does not interact with the SAM binding pocket. The 7-(3-pyrrolidin-1-yl-) propoxy side
chain of UNC0638 interacts with the lysine binding channel.
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Figure 2. UNC0638 inhibits cellular H3K9 dimethylation and shows good separation of
functional potency and toxicity in MDA-MB-231 cells
(a) UNC0638 (48 h) or G9a and/or GLP shRNAs, reduced H3K9 dimethylation levels.
H3K9me2 antibody was used for cell immunostaining (in-cell western) and results
normalized to cell number measured by uptake nucleic acid dye (DRAQ5). (b) UNC0638
was considerably more potent than BIX01294 and UNC0737 (negative control) in reducing
cellular H3K9me2 levels, which were measured after MDA-MB-231 cells were treated with
inhibitors for 48 h. Dashed line indicates level of H3K9me2 resulting from G9a and GLP
knockdown. (c) Cellular levels of H3K9me2 were progressively reduced from 1 d to 4 d
exposure to UNC0638 at three concentrations (80 nM, representing IC50; 250 nM,
representing IC90; and 500 nM, representing 2 × IC90). The reductions with 250-nM and
500-nM treatments after 4 d were equal or very close to that of G9a and GLP knockdown
cells. Refreshing the inhibitor after 2 d (2+2d) increased inhibition by UNC0638 at 80 nM
but had little further effect at 250 and 500 nM. The effects of UNC0638 were long-lasting.
In cells with 2 d exposure to UNC0638, levels of H3K9me2 remained low after washout of
compound followed by 2 d incubation without the inhibitor (2+2dw). (d) UNC0638 and
UNC0737 had lower cellular toxicity than BIX01294 in MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide)) assays. (e,f) UNC0638 had good separation of
functional potency (decrease in H3K9me2 levels) and toxicity (from the MTT assay),
whereas BIX01294 had poor separation of these effects.
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Figure 3. Quantitative MS analysis of histone post-translational modifications in MDA-MB-231
cells
(a–d) MS of doubly charged peptides (KSTGGKAPR) corresponding to H3K9me2 (a,b)
and H3K9me3 (c,d). In a,c, cells were treated with indicated shRNAs (control, D0 propionyl
labeled; G9a, D0,D5 propionyl labeled, ~2.5 m/z heavier than the control; G9a + GLP,
D5,D5 propionyl labeled, ~5 m/z heavier than the control). In b,d, cells were mock-treated
(control, D0 propionyl labeled) or treated with 1 μM of BIX01294 (D0,D5 propionyl
labeled, ~2.5 m/z heavier than the control) or UNC0638 (D5,D5 propionyl labeled, ~5 m/z
heavier than the control) for 48 h.
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Figure 4. Effects of UNC0638 on H3K9me2 and DNA methylation
(a) Example of a genomic region (3p24.3) showing reductions in H3K9me2 after UNC0638
exposure (P = 2.0 × 10−10). Light blue bars show the log ratios of anti-H3K9me2 to IgG in
control (top) and treated (bottom) samples. (b) Administration of UNC0638 decreased
H3K9me2 in the MAGEA1 promoter. Log ratios are shown as in a. The promoter was
defined to be 4 kilobase pairs upstream and 0.5 kilobase pairs downstream of the
transcription start site. (c) UNC0638 did not change DNA methylation levels. MCF7 cells
were exposed to either UNC0638 (at 70 or 320 nM), 5-azacytidine (DAC) or control. y-axis
scale is the excess of the number of significantly hypomethylated probes over the number of
hypermethylated probes on chromosome 3. Significance cutoff was set at P = 10−3 for two-
sample t-test between treated and control log intensities.
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Figure 5. UNC0638 reactivates a silent EGFP retrovirus vector and G9a-regulated endogenous
genes in mES cells
(a) Time course of EGFP retrovirus activation during indicated treatments in J1 mES cells
infected by HSC1-EF1α-EGFP-Puromycin retroviral vector. Plotted percentage of EGFP
expression is the mean of the percentage of EGFP+ cells in three independent experiments.
Error bars, s.d. (b) Analysis of mRNA levels of two G9a-regulated endogenous genes
(MAGEA2 and DUB1) in J1 mES cells treated for 10 d with indicated compounds. The
graph shows the normalized expression of MAGEA2 and DUB1 relative to the mRNA level
detected in untreated cells (Δ(ΔCt)). (c,d) ChIP analysis of H3K9me2 enrichment at the
EGFP gene (c) and MAGEA2 promoter (d) in cells treated with UNC0638 (500 nM) for 3
or 7 d. (e) Analysis of DNA methylation in the long terminal repeat (LTR) of the HSC1-
EF1α-EGFP-Puromycin retroviral vector and in the MAGEA2 promoter after 10 d of
treatment.
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Scheme 1. Discovery of UNC0638
Structure-based design and SAR exploration of the quinazoline template represented by
BIX01294 led to the identification of UNC0321, a G9a and GLP inhibitor with high in vitro
potency but poor cellular potency. The design and synthesis of several generations of new
analogs aimed at improving cell membrane permeability while maintaining high in vitro
potency resulted in the discovery of UNC0638, which has balanced in vitro potency and
physicochemical properties aiding cell penetration. UNC0737, the N-methyl analog of
UNC0638, was discovered as a structurally similar but less potent G9a and GLP inhibitor
for use as a negative control.
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Table 1



































JMJD2E 4,500 ± 1,100
f NT
DNMT1 107,000 ± 6,000
g NT
a
IC50 or Ki values are the average of at least two separate experiments.
b










Radioactive methyl transfer assay results. NT, not tested. ND, not detected.
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